Back to the list
Congress: ECR25
Poster Number: C-27014
Type: Poster: EPOS Radiologist (scientific)
Authorblock: I. Stamouli1, I. Gatos1, P. Katsakiori1, S. Tsantis1, T. Kalathas2, V. Chatzipavlidou2, N. Papathanasiou1, G. Kagadis1; 1Rion/GR, 2Thessaloniki/GR
Disclosures:
Ioanna Stamouli: Nothing to disclose
Ilias Gatos: Nothing to disclose
Paraskevi Katsakiori: Nothing to disclose
Stavros Tsantis: Nothing to disclose
Theodoros Kalathas: Nothing to disclose
Vasiliki Chatzipavlidou: Nothing to disclose
Nikos Papathanasiou: Nothing to disclose
George Kagadis: Nothing to disclose
Keywords: Artificial Intelligence, Molecular imaging, Nuclear medicine, PET-CT, CAD, Molecular imaging, Segmentation, Cancer, Molecular, genomics and proteomics, Multidisciplinary cancer care
References

[1]       Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2022. CA Cancer J Clin 2022;72:7–33. https://doi.org/10.3322/caac.21708.

[2]       Cornford P, van den Bergh RCN, Briers E, Van den Broeck T, Cumberbatch MG, De Santis M, et al. EAU-EANM-ESTRO-ESUR-SIOG Guidelines on Prostate Cancer. Part II—2020 Update: Treatment of Relapsing and Metastatic Prostate Cancer. Eur Urol 2021;79:263–82. https://doi.org/10.1016/j.eururo.2020.09.046.

[3]       Hofman MS, Lawrentschuk N, Francis RJ, Tang C, Vela I, Thomas P, et al. Prostate-specific membrane antigen PET-CT in patients with high-risk prostate cancer before curative-intent surgery or radiotherapy (proPSMA): a prospective, randomised, multicentre study. The Lancet 2020;395:1208–16. https://doi.org/10.1016/S0140-6736(20)30314-7.

[4]       Carvalho J, Nunes P, Da Silva ET, Silva R, Lima J, Quaresma V, et al. [68Ga]Ga-PSMA-11 PET-CT: Local preliminary experience in prostate cancer biochemical recurrence patients. Archivio Italiano Di Urologia e Andrologia 2021;93:21–5. https://doi.org/10.4081/aiua.2021.1.21.

[5]       Awenat S, Piccardo A, Carvoeiras P, Signore G, Giovanella L, Prior JO, et al. Diagnostic Role of 18F-PSMA-1007 PET/CT in Prostate Cancer Staging: A Systematic Review. Diagnostics 2021;11:552. https://doi.org/10.3390/diagnostics11030552.

[6]       Lawhn-Heath C, Salavati A, Behr SC, Rowe SP, Calais J, Fendler WP, et al. Prostate-specific Membrane Antigen PET in Prostate Cancer. Radiology 2021;299:248–60. https://doi.org/10.1148/radiol.2021202771.

[7]       Hofman MS, Hicks RJ, Maurer T, Eiber M. Prostate-specific Membrane Antigen PET: Clinical Utility in Prostate Cancer, Normal Patterns, Pearls, and Pitfalls. RadioGraphics 2018;38:200–17. https://doi.org/10.1148/rg.2018170108.

[8]       Barbosa FG, Queiroz MA, Nunes RF, Viana PCC, Marin JFG, Cerri GG, et al. Revisiting Prostate Cancer Recurrence with PSMA PET: Atlas of Typical and Atypical Patterns of Spread. RadioGraphics 2019;39:186–212. https://doi.org/10.1148/rg.2019180079.

 
GALLERY